159 related articles for article (PubMed ID: 10807693)
1. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
[TBL] [Abstract][Full Text] [Related]
2. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF
Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537
[TBL] [Abstract][Full Text] [Related]
3. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.
van Houwelingen KP; van Dijk BA; Hulsbergen-van de Kaa CA; Schouten LJ; Gorissen HJ; Schalken JA; van den Brandt PA; Oosterwijk E
BMC Cancer; 2005 Jun; 5():57. PubMed ID: 15932632
[TBL] [Abstract][Full Text] [Related]
5. An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.
Gossage L; Pires DE; Olivera-Nappa Á; Asenjo J; Bycroft M; Blundell TL; Eisen T
Hum Mol Genet; 2014 Nov; 23(22):5976-88. PubMed ID: 24969085
[TBL] [Abstract][Full Text] [Related]
6. Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.
Schraml P; Hergovich A; Hatz F; Amin MB; Lim SD; Krek W; Mihatsch MJ; Moch H
Am J Pathol; 2003 Sep; 163(3):1013-20. PubMed ID: 12937142
[TBL] [Abstract][Full Text] [Related]
7. Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated ccRCC.
Li L; Bao H; Xu Y; Yang W; Zhang Z; Ma K; Zhang K; Zhou J; Gong Y; Ci W; Gong K
Mol Diagn Ther; 2023 Nov; 27(6):741-752. PubMed ID: 37587253
[TBL] [Abstract][Full Text] [Related]
8. Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
Batavia AA; Rutishauser D; Sobottka B; Schraml P; Beerenwinkel N; Moch H
Mod Pathol; 2023 Aug; 36(8):100194. PubMed ID: 37088333
[TBL] [Abstract][Full Text] [Related]
9. Does the VHL polymorphisms rs779805 and rs1642742 affect renal cell carcinoma susceptibility, prognosis and survival in Central European population?
Chrabańska M; Szweda-Gandor N; Drozdzowska B
Medicine (Baltimore); 2023 Dec; 102(50):e36540. PubMed ID: 38115281
[TBL] [Abstract][Full Text] [Related]
10. VHL mutation drives human clear cell renal cell carcinoma progression through PI3K/AKT-dependent cholesteryl ester accumulation.
Zhang S; Fang T; He Y; Feng W; Yu Z; Zheng Y; Zhang C; Hu S; Liu Z; Liu J; Yu J; Zhang H; He A; Gong Y; He Z; Yang K; Xi Z; Yu W; Zhou L; Yao L; Yue S
EBioMedicine; 2024 May; 103():105070. PubMed ID: 38564827
[TBL] [Abstract][Full Text] [Related]
11. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma.
McRonald FE; Morris MR; Gentle D; Winchester L; Baban D; Ragoussis J; Clarke NW; Brown MD; Kishida T; Yao M; Latif F; Maher ER
Mol Cancer; 2009 Jun; 8():31. PubMed ID: 19493342
[TBL] [Abstract][Full Text] [Related]
12. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma.
Hu J; Tan P; Ishihara M; Bayley NA; Schokrpur S; Reynoso JG; Zhang Y; Lim RJ; Dumitras C; Yang L; Dubinett SM; Jat PS; Van Snick J; Huang J; Chin AI; Prins RM; Graeber TG; Xu H; Wu L
Signal Transduct Target Ther; 2023 Apr; 8(1):155. PubMed ID: 37069149
[TBL] [Abstract][Full Text] [Related]
13. Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein.
Rao H; Li X; Liu M; Liu J; Li X; Xu J; Li L; Gao WQ
Oncogene; 2020 May; 39(19):3853-3866. PubMed ID: 32161311
[TBL] [Abstract][Full Text] [Related]
14. The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
Cinque A; Minnei R; Floris M; Trevisani F
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358771
[TBL] [Abstract][Full Text] [Related]
15. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function.
Liakopoulos D; Büsgen T; Brychzy A; Jentsch S; Pause A
Proc Natl Acad Sci U S A; 1999 May; 96(10):5510-5. PubMed ID: 10318914
[TBL] [Abstract][Full Text] [Related]
16. Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel-Lindau gene in the ccRCC.
Chesnel F; Jullion E; Delalande O; Couturier A; Alusse A; Le Goff X; Lenglet M; Gardie B; Abadie C; Arlot-Bonnemains Y
Br J Cancer; 2022 Nov; 127(11):1954-1962. PubMed ID: 36175619
[TBL] [Abstract][Full Text] [Related]
17. Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.
Mitchell TJ; Turajlic S; Rowan A; Nicol D; Farmery JHR; O'Brien T; Martincorena I; Tarpey P; Angelopoulos N; Yates LR; Butler AP; Raine K; Stewart GD; Challacombe B; Fernando A; Lopez JI; Hazell S; Chandra A; Chowdhury S; Rudman S; Soultati A; Stamp G; Fotiadis N; Pickering L; Au L; Spain L; Lynch J; Stares M; Teague J; Maura F; Wedge DC; Horswell S; Chambers T; Litchfield K; Xu H; Stewart A; Elaidi R; Oudard S; McGranahan N; Csabai I; Gore M; Futreal PA; Larkin J; Lynch AG; Szallasi Z; Swanton C; Campbell PJ;
Cell; 2018 Apr; 173(3):611-623.e17. PubMed ID: 29656891
[TBL] [Abstract][Full Text] [Related]
18. Molecular diagnosis and therapy of kidney cancer.
Linehan WM; Bratslavsky G; Pinto PA; Schmidt LS; Neckers L; Bottaro DP; Srinivasan R
Annu Rev Med; 2010; 61():329-43. PubMed ID: 20059341
[TBL] [Abstract][Full Text] [Related]
19. VHL governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas.
Lee H; Zhuang L; Gan B
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618953
[TBL] [Abstract][Full Text] [Related]
20. Sharing the initial experience of pan-cancer panel analysis in high-risk renal cell carcinoma in the Korean population.
Suh J; Jeong CW; Choi S; Ku JH; Kim HH; Kim K; Kwak C
BMC Urol; 2020 Aug; 20(1):125. PubMed ID: 32811483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
